Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Slides:

Advertisements

Similar presentations

You can never be too Thin…. An Update on NOACs

Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Oral Anticoagulants and Reversal Agents

Anticoagulants in Interventional Cardiology:

NOACs In Long-term VTE Treatment: A State Of The Art Review

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Select Topics in Cardiovascular Medicine

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

New Oral Anticoagulants and VTE Management

Real-World Safety of NOACs: What Do We Know Today?

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

DOACs and Urgent Bleeding

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

NOAC Studies in VTE AF Studies Superior Outcomes.

Iron Deficiency in Heart Failure

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

NOACs and Reversal Agents

VKA Reversal and LVADs.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

My PAH Patient.

Perspectives on Revised European Guidelines on Management of Bleeding and Coagulopathy Following Major Trauma.

PCSK9 Inhibitors and Real-World Evidence

Extraordinary Cases in Stroke Prevention

The Power of As-Treated Analyses

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents

Introduction/Overview

VKA-Associated Bleeding: Results From the RADOA Registry

Reversal Agents for VKA-Associated Anticoagulation

Management of Urgent Anticoagulation Reversal: 4F-PCC vs FFP

Anticoagulation Reversal Strategies for Platelet Aggregation Inhibitors

Anticoagulation Reversal With Vitamin K

FFP for Anticoagulation Reversal

Protocols Needed to Improve Treatment of Patients in Need of Anticoagulation Reversal

Recent Anticoagulation Reversal Clinical Trials

4F-PCC vs FFP: A Systematic Review and Meta-Analysis, Mortality Results

4F-PCC vs FFP: A Systematic Review and Meta-Analysis, Additional Outcomes

4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Primary Endpoint Results

NOACs Compared With Warfarin for Bleeding Endpoints

NOAC Anticoagulation Reversal Agents

Scientific Rationale for Use of 4F-PCC in Bleeding Anticoagulated Patients: Results From a Phase 3b Trial

Results of a Skin-Punch Biopsy Study on Edoxaban Bleeding and Reversal by 4F-PCC

Updated European Heart Rhythm Association Practical Guide: Management of NOAC-Associated Bleeding

RADOA Registry: Patient Recruitment

RADOA Registry: Reversal of NOACs, VKAs - Preliminary Findings and Unresolved Issues

4F-PCC for Warfarin-Associated Intracranial Hemorrhage

What Do Guidelines Recommend for Anticoagulation Reversal?

Summary and Conclusions

Abbreviations

Abbreviations (cont)